Improving the effectiveness of antifungal treatments for Aspergillus infections
Unlocking the cidal activity of echinocandins against Aspergillus fumigatus
This study is looking at how to make antifungal drugs work better against a tough mold called Aspergillus fumigatus, which can be a serious problem for people with weakened immune systems, by figuring out how the mold survives treatment and finding new ways to help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-11059867 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of echinocandins, a class of antifungal drugs, against Aspergillus fumigatus, a common and dangerous mold infection in immunocompromised patients. The study aims to understand how this fungus adapts to stress and survives treatment, which could lead to better therapeutic strategies. By using advanced gene-editing techniques, researchers are creating a library of mutants to identify specific mechanisms that contribute to the fungus's resistance. This could pave the way for new combination therapies that improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are immunocompromised individuals at risk for invasive aspergillosis.
Not a fit: Patients who do not have invasive aspergillosis or are not immunocompromised may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for invasive aspergillosis, reducing mortality rates among affected patients.
How similar studies have performed: Previous research has shown promise in improving antifungal treatments through similar approaches, but this specific investigation into echinocandin efficacy is novel.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Fortwendel, Jarrod R. — University of Tennessee Health Sci Ctr
- Study coordinator: Fortwendel, Jarrod R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.